within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA03_Melphalan;

model Melphalan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 7.266666666666667e-06,
    adminDuration = 600,
    adminMass = 140 / 1000000,
    adminCount = 1,
    Vd = 0.0482,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0193,
    k12 = 3.4333333333333332e-06,
    k21 = 3.4333333333333332e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Melphalan</td></tr><tr><td>ATC code:</td><td>L01AA03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>140</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>48.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.436</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Melphalan is an alkylating agent used in the treatment of multiple myeloma and ovarian cancer. It works by cross-linking DNA, thus inhibiting DNA and RNA synthesis and leading to cell death. It is still approved and in clinical use, particularly for hematological malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult patients with multiple myeloma receiving intravenous melphalan for conditioning therapy prior to stem cell transplantation.</p><h4>References</h4><ol><li><p>Nath, CE, et al., &amp; Earl, J (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. <i>British journal of clinical pharmacology</i> 69(5) 484–497. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2010.03638.x\">10.1111/j.1365-2125.2010.03638.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20573084/\">https://pubmed.ncbi.nlm.nih.gov/20573084</a></p></li><li><p>Nath, CE, et al., &amp; Earl, JW (2007). Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. <i>British journal of clinical pharmacology</i> 64(2) 151–164. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2007.02862.x\">10.1111/j.1365-2125.2007.02862.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17324241/\">https://pubmed.ncbi.nlm.nih.gov/17324241</a></p></li><li><p>Mougenot, P, et al., &amp; Bressolle, F (2004). Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. <i>Cancer chemotherapy and pharmacology</i> 53(6) 503–512. DOI:<a href=\"https://doi.org/10.1007/s00280-003-0761-2\">10.1007/s00280-003-0761-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15007638/\">https://pubmed.ncbi.nlm.nih.gov/15007638</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01AA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Melphalan;
